One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for ...
Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...
World-leading challenge study expertise helping deliver scalable, high-quality outpatient vaccine trials in healthy ...
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in ...
Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...
Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...
Via well-designed AI tools and workflows, trial sponsors are aiming to unify cross-functional data ecosystems to enable a ...
Background Extensions to Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and Consolidated Standards of Reporting Trials (CONSORT) reporting recommendations specifically for ...
Cancer clinical trials development in Latin America underperforms globally yet strengths could expand equitable evidence worldwide. A review of the current landscape argues that Latin America, despite ...
Just like the moment a mosquito bites, the shot of dengue virus I received in my arm was so quick and painless that afterward I wasn't even sure it happened at all. A few years ago, I wrote a story ...
Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback